UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of October 2025
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 21 October 2025, London UK
GSK provides update on latozinemab
LONDON, 21 October 2025 -GSK plc
(LSE/NYSE: GSK) and Alector,
Inc. (Nasdaq: ALEC) today
confirmed headline results from the INFRONT-3 clinical trial
evaluating latozinemab in individuals with frontotemporal dementia
due to a mutation in the progranulin gene (FTD-GRN).
Although latozinemab treatment resulted in a statistically
significant effect on the INFRONT-3 biomarker co-primary endpoint
of plasma progranulin (PGRN) concentrations[i],
latozinemab did not show benefit on the clinical co-primary
endpoint of slowing FTD-GRN progression.
The secondary and exploratory endpoints also did not demonstrate
treatment-related effects on FTD-GRN.
Preliminary safety data have not highlighted any major safety
concerns at present. More in-depth analysis of the data is
ongoing.
Based on these results, the open-label extension portion of the
INFRONT-3 trial and the continuation study for latozinemab will be
discontinued.
Given
the unmet medical need in neurodegeneration, innovation in this
area is still needed. GSK will evaluate the totality of these data
to inform future research.
The full results of the INFRONT-3 study will be presented at an
upcoming medical congress.
GSK and Alector Collaboration
In July 2021, GSK and Alector entered into a collaboration and
license agreement to collaborate on the global development and
commercialization of progranulin-elevating monoclonal antibodies,
including latozinemab. Alector led the global clinical development
of latozinemab through Phase 2 proof-of-concept. Thereafter,
Alector and GSK shared development responsibilities and all costs
for global development were divided between the two
companies.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com.
|
GSK enquiries
|
|
|
|
|
Media:
|
Simon
Steel
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Sarah
Clements
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
Lyndsay
Meyer
|
+1 202
302 4595
|
(Washington
DC)
|
|
|
|
|
|
|
|
|
|
|
|
Investor
Relations:
|
Constantin
Fest
|
+44 (0)
7831 826525
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Steph
Mountifield
|
+44 (0)
7796 707505
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
Frannie
DeFranco
|
+1 215
751 3126
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the "Risk
Factors" section in GSK's Annual Report on Form 20-F for 2024, and
GSK's Q2 Results for 2025.
Registered in England & Wales:
No.
3888792
Registered Office:
79
New Oxford Street
London
WC1A
1DG
References
i GSK
data on file
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: October
22, 2025
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|
